25.7 C
New York
Thursday, June 4, 2026

Tag: response

newssourceFORcompanyinformationcontent1marketreleases

Nando’s Brings Soccer Legend Bukayo Saka’s Viral ‘Saka Sauce’ to America

The fast-casual favorite known for its flame-frilled chicken marks the summer's biggest tournament with first Free Chicken and Chips Day on June 12th, watch...

Water Mission and mWater Partner to Strengthen Remote Monitoring and WASH Program Management

NEWS | Water Mission and mWater Partner to Strengthen Remote Monitoring and WASH Program Management

TCL Applies its Award Winning QD-Mini LED Display Technology to Level Up Premium Gaming Monitors

Delivering the Ultimate AAA Gameplay Experience, Display Leader Introduces Three New QD-Mini LED Gaming MonitorsIRVINE, Calif., June 4, 2026 /PRNewswire/ -- TCL®, one of the world's...

HKC, ANTGAMER and KOORUI Unveil Breakthrough Display Innovations at COMPUTEX 2026

NEW YORK, June 4, 2026 /PRNewswire/ -- HKC, ANTGAMER and KOORUI made a joint appearance at COMPUTEX 2026 under the theme "Win Beyond the...

Buzz Bomb Emphasizes Sugar-Free, Easy-Access Energy To Keep Daily Energy Levels High

Clean, Healthy Energy Options Are in Demand. So Are Sugar-Free Ones. Buzz Bomb Answers Both Needs.FORT LAUDERDALE, Fla., June 4, 2026 /PRNewswire/ -- Americans...

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources 
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

Parsons Accelerates Mission Success with Advanced AI

Key Takeaways:

Best Stylish Prescription Glasses for Work and Everyday Wear in 2026: Quay Named a Top Pick for Fashion-Forward RX Frames by Better Business Advice

NEW YORK, June 4, 2026 /PRNewswire/ -- In response to shifting demand across professional and everyday settings, Better Business Advice has recognized Quay for its...

Delta Thailand Showcases Integrated Building Automation Solutions for Smarter, Healthier and More Sustainable Spaces at NOVA Expo 2026

BANGKOK, June 4, 2026 /PRNewswire/ -- Delta Electronics (Thailand) Public Company Limited, a global leader in power management and smart green solutions, is presenting...

Leetx Unveils 2026 European Roadshow, Bringing Full-Range Industrial Assembly Technology Closer to EU Manufacturers

Five-stop trade show roadmap across Germany, Spain and Poland to showcase transducerized tightening, servo pressing, automated screw feeding and precision dispensing solutionsMUNICH, June 4,...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

2026 ASCO LBA | Juncell Therapeutics’ GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma

SHANGHAI, June 3, 2026 /PRNewswire/ -- On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical...

POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding

Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S. 
Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResponse

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers